|
04 Aug 2020 |
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency
|
|
04 Aug 2020 |
Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real Time During Breast Cancer Surgery
|
|
04 Aug 2020 |
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
|
|
31 Jul 2020 |
Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)
|
|
29 Jul 2020 |
Versant Ventures Launches Bright Peak Therapeutics
|
|
27 Jul 2020 |
Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi®
|
|
22 Jul 2020 |
AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated
|
|
22 Jul 2020 |
Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis
|
|
22 Jul 2020 |
Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors
|
|
21 Jul 2020 |
Blue Earth Diagnostics Announces Dosing of Initial Patients in Phase 3 SPOTLIGHT Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Biochemically Recurrent Prostate Cancer
|
|
21 Jul 2020 |
NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
|
|
21 Jul 2020 |
Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343
|
|
21 Jul 2020 |
Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020
|
|
20 Jul 2020 |
Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients
|
|
20 Jul 2020 |
Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma
|
|
20 Jul 2020 |
Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol
|
|
14 Jul 2020 |
INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease
|
|
10 Jul 2020 |
Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)
|
|
10 Jul 2020 |
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
|
|
09 Jul 2020 |
Croma-Pharma announces submission for their botulinum toxin to treat glabellar (frown) lines to the German authority BfArM
|
|
08 Jul 2020 |
NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors
|
|
08 Jul 2020 |
Evive Biotech meets primary and secondary endpoints in global Phase III clinical trial for their novel chemotherapy-induced neutropenia treatment
|
|
07 Jul 2020 |
U.S. FDA Approves Qwo™ (collagenase clostridium histolyticum-aaes), the First Injectable Treatment for Cellulite
|
|
06 Jul 2020 |
EspeRare Receives FDA Breakthrough Therapy Designation for Investigational Prenatal Treatment ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
|
|
06 Jul 2020 |
Insulin aspart Sanofi® receives EU marketing authorization, broadening options and increasing treatment choice for people with diabetes
|
